Literature DB >> 26115803

Prognostic Factors in the Operative Management of Sacral Chordomas.

Babar Kayani1, Mathew David Sewell2, Kimberly-Anne Tan3, Sammy A Hanna1, Richard Williams4, Robin Pollock1, John Skinner1, Timothy W R Briggs1.   

Abstract

OBJECTIVE: Surgical resection of sacral chordomas offers the best long-term prognosis but has high rates of local recurrence, metastases, and mortality. Most prognostic studies are limited by low patient numbers, variation in treatment, follow-up, and prognostic variables studied. The objective of this study was to identify factors associated with recurrence, metastasis, and survival.
METHODS: Retrospective review of 58 patients undergoing sacrectomy for chordoma with a mean age of 63 years (range: 41-80 years) and a mean follow-up of 45.3 months (range: 2-144 months). Data on prognostic variables and outcomes were collected. Forty-two patients underwent a combined anterior and posterior approach and 16 underwent a posterior-only approach.
RESULTS: Twenty-six patients (44.8%) died during follow-up. Kaplan-Meier estimates for 5- and 10-year survival were 62% and 26%, respectively. Local recurrence occurred in 32 patients (51.7%) and metastases in 19 (32.7%). Adequacy of resection margins was the most important predictor of disease recurrence, metastases, and survival. Tumors >8 cm were associated with significantly increased risk of metastases and reduced survival (P < 0.05). Dedifferentiated disease and infiltration of the sacroiliac joints and/or adjacent musculature were also associated with reduced survival. Median survival was 23 months for patients with gluteus maximus invasion, 66 months for gluteus maximus and piriformis invasion, 67 months for piriformis invasion, and 90 months for patients with no muscle invasion.
CONCLUSIONS: Patients with inadequate resection margins, tumors >8 cm, sacroiliac joint and/or musculature infiltration, and dedifferentiated disease have significantly worse oncologic outcomes. Involvement of gluteus maximus alone confers a higher risk of metastases and local recurrence than involvement of piriformis and gluteus maximus, or piriformis alone.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chordoma; Metastasis; Mortality; Prognostic variables; Recurrence; Survival

Mesh:

Year:  2015        PMID: 26115803     DOI: 10.1016/j.wneu.2015.06.030

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  14 in total

1.  Letter to the Editor concerning "Surgical treatment of sacral chordoma: survival and prognostic factors" by C. Ruosi et al. (Eur Spine J; 2015; 24(Suppl 7):S912-S917.

Authors:  Ming-Xiang Zou; Guo-Hua Lv; Xiao-Bin Wang; Jing Li
Journal:  Eur Spine J       Date:  2016-10-18       Impact factor: 3.134

2.  Low dose radiotherapy is associated with local complications but not disease control in sacral chordoma.

Authors:  Matthew T Houdek; Peter S Rose; Mario Hevesi; Joseph H Schwab; Anthony M Griffin; John H Healey; Ivy A Petersen; Thomas F DeLaney; Peter W Chung; Michael J Yaszemski; Jay S Wunder; Francis J Hornicek; Patrick J Boland; Franklin H Sim; Peter C Ferguson
Journal:  J Surg Oncol       Date:  2019-02-07       Impact factor: 3.454

3.  Surgical Management of Sacral Chordomas: Illustrative Cases and Current Management Paradigms.

Authors:  Arjun V Pendharkar; Allen L Ho; Eric S Sussman; Atman Desai
Journal:  Cureus       Date:  2015-08-12

4.  Upregulated human telomerase reverse transcriptase (hTERT) expression is associated with spinal chordoma growth, invasion and poor prognosis.

Authors:  Ming-Xiang Zou; Guo-Hua Lv; Jing Li; Xiao-Ling She; Yi Jiang
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

5.  Imaging of spinal chordoma and benign notochordal cell tumor (BNCT) with radiologic pathologic correlation.

Authors:  Mark D Murphey; Matthew J Minn; Alejandro Luiña Contreras; Kelly K Koeller; Robert Y Shih; Carrie Y Inwards; Takehiko Yamaguchi
Journal:  Skeletal Radiol       Date:  2022-09-05       Impact factor: 2.128

6.  Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis.

Authors:  Ming-Xiang Zou; An-Bo Peng; Guo-Hua Lv; Xiao-Bin Wang; Jing Li; Xiao-Ling She; Yi Jiang
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

7.  Surgical treatment of sacral chordoma: survival and prognostic factors.

Authors:  C Ruosi; G Colella; S L Di Donato; F Granata; M G Di Salvatore; F Fazioli
Journal:  Eur Spine J       Date:  2015-10-12       Impact factor: 3.134

Review 8.  Surgical Management of Skull Base and Spine Chordomas.

Authors:  Joel Z Passer; Christopher Alvarez-Breckenridge; Laurence Rhines; Franco DeMonte; Claudio Tatsui; Shaan M Raza
Journal:  Curr Treat Options Oncol       Date:  2021-03-20

9.  High expression of Sam68 in sacral chordomas is associated with worse clinical outcomes.

Authors:  Hai Wen; Pengzhi Li; Hong Ma; Jiaoyun Zheng; Yipin Yu; Guohua Lv
Journal:  Onco Targets Ther       Date:  2017-09-22       Impact factor: 4.147

10.  Outcomes of Surgery for Sacral Chordoma and Impact of Complications: A Report of 50 Consecutive Patients With Long-Term Follow-Up.

Authors:  Scott L Zuckerman; Sun-Ho Lee; George J Chang; Garrett L Walsh; Reza J Mehran; Ziya L Gokaslan; Ganesh Rao; Claudio E Tatsui; Laurence D Rhines
Journal:  Global Spine J       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.